Form 4: Incyte R&D President Details Future Equity Awards and Tax-Related Stock Dispositions

Incyte Corporation's President of R&D, Pablo J. Cagnoni, has filed a Form 4 detailing future equity awards including restricted stock units, performance shares, and stock options, alongside tax-related share dispositions, all scheduled for mid-July 2025.

Summary

• Pablo J. Cagnoni, President, R&D, reported future transactions for July 14 and 15, 2025, filed under a Rule 10b5-1(c) plan.
• On July 14, 2025, 1,280 shares of common stock were disposed of at $69.98 per share to satisfy tax withholding obligations.
• On July 15, 2025, an additional 2,628 shares of common stock were disposed of at $68.25 per share for tax withholding purposes.
• On July 15, 2025, Cagnoni was awarded 17,538 restricted stock units (RSUs) at a price of $0, which will vest 25% annually over four years.
• Also on July 15, 2025, 43,846 performance shares were acquired at $0, with potential to receive up to 200% of one common share based on Incyte's relative total shareholder return (TSR) over a three-year period starting January 1, 2025. These shares will vest on July 15, 2028.
• Additionally, on July 15, 2025, 39,471 employee stock options were acquired at an exercise price of $68.25, expiring on July 14, 2035, with vesting beginning after one year (25%) and the remainder monthly over three years.
• Following these transactions, Cagnoni will beneficially own 234,800 shares of common stock directly, including 229,661 shares from previously reported unvested restricted stock units and earned performance stock units.

Sentiment

Score: 7

Explanation: The filing indicates significant equity awards to a key executive, aligning their interests with shareholders and incentivizing long-term performance. While there are tax-related dispositions, these are standard. The pre-planned nature of the transactions under a 10b5-1 plan adds transparency and predictability.

Positives

• Grant of significant equity awards (17,538 RSUs, 43,846 performance shares, and 39,471 stock options) to a key executive aligns management's interests with shareholder value creation.
• Performance shares are tied to relative Total Shareholder Return (TSR) over a three-year period, incentivizing outperformance against a fixed peer group.
• The awards demonstrate continued commitment to executive retention and motivation within the company.

Negatives

• Dispositions of 1,280 shares at $69.98 and 2,628 shares at $68.25 for tax withholding reduce direct beneficial ownership, though this is a standard practice for equity compensation.

Risks

• The ultimate value of performance shares is contingent on Incyte's relative Total Shareholder Return (TSR) compared to a peer group, introducing market performance risk.
• The vesting of restricted stock units and stock options is subject to the reporting person's continued service with the issuer, posing a risk if employment ceases.

Future Outlook

The document outlines future vesting schedules for restricted stock units (25% annually over four years), performance shares (vesting on July 15, 2028, based on TSR performance over a three-year period starting January 1, 2025), and employee stock options (25% vesting after one year, remainder monthly over three years).

Industry Context

Equity compensation, including restricted stock units, performance shares, and stock options, is a standard practice in the biotechnology and pharmaceutical industry to attract, retain, and incentivize key executives, aligning their long-term interests with company performance and shareholder value.

Stakeholder Impact

• Shareholders: The equity awards align the interests of a key executive with shareholder value creation, potentially leading to improved long-term performance.
• Employees: Reflects standard executive compensation practices, which can influence overall compensation philosophy within the company.

Next Steps

• Annual vesting of restricted stock units over the next four years.
• Assessment of Incyte's relative Total Shareholder Return (TSR) performance over the three-year period starting January 1, 2025, for performance share determination.
• Vesting of performance shares on July 15, 2028.
• Vesting of employee stock options over the next four years, starting one year after the grant date.

Key Dates

Keywords

Incyte Corp, INCY, Form 4, SEC filing, insider trading, beneficial ownership, restricted stock units, RSUs, performance shares, stock options, executive compensation, Pablo J. Cagnoni, equity awards, corporate governance